Expert Opinion on Pharmacotherapy最新文献_第10页

The effects of prenatal exposure to opioids on early childhood development: context matters most. 产前接触阿片类药物对儿童早期发育的影响：环境最重要。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-06-13 DOI: 10.1080/14656566.2024.2365331

Ginny Carter, Sarah McGlothlin, Skye McLaurin-Jiang, Rebecca B Carlson, Kevin E O'Grady, Hendree E Jones

{"title":"The effects of prenatal exposure to opioids on early childhood development: context matters most.","authors":"Ginny Carter, Sarah McGlothlin, Skye McLaurin-Jiang, Rebecca B Carlson, Kevin E O'Grady, Hendree E Jones","doi":"10.1080/14656566.2024.2365331","DOIUrl":"10.1080/14656566.2024.2365331","url":null,"abstract":"Introduction: The opioid crisis has brought an increasing focus on the long-term outcomes of children following prenatal opioid exposure. Evidence to date has been conflicting, which has caused confusion and concern amongst parents, caregivers, social service providers, medical providers and policy makers.Methods: This review systematically evaluated the highest quality studies relating prenatal exposure to opioids with early childhood developmental outcomes. It focused on developmental outcomes as measured by the Bayley Scales of Infant and Toddler Development, encompassing cognitive, motor, and psychosocial domains of child development.Results: Although several articles reported correlations between prenatal opioid exposure and poor early childhood developmental outcomes, these relationships were no longer statistically significant after adjusting for socio-environmental factors.Conclusion: Additional research is needed to determine the extent of any relationship of socio-environmental factors with early childhood development in children prenatally exposed to opioids. This review suggests that socio-environmental factors may be significantly related to poor early childhood outcomes in the presence of prenatal opioid exposure.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in JAK2 inhibition for the treatment of myelofibrosis. 抑制 JAK2 以治疗骨髓纤维化的最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-07-01 DOI: 10.1080/14656566.2024.2372453

Noa Rippel, Marina Kremyanskaya

{"title":"Recent advances in JAK2 inhibition for the treatment of myelofibrosis.","authors":"Noa Rippel, Marina Kremyanskaya","doi":"10.1080/14656566.2024.2372453","DOIUrl":"10.1080/14656566.2024.2372453","url":null,"abstract":"Introduction: Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, cytopenias, a potential for leukemic transformation, and increased mortality. Patients who are ineligible for stem cell transplant rely on pharmacologic therapies of noncurative intent, whose cornerstone consists of JAK inhibitors (JAKi). While current JAKi are efficacious in controlling symptoms and splenic volume, none meaningfully reduce clonal burden nor halt disease progression, and patients oftentimes develop JAKi intolerant, relapsed, or refractory MF. As such, there remains an urgent necessity for second-line options and novel therapies with disease-modifying properties.Areas covered: In this review, we delineate the mechanistic rationale, along with the latest safety and efficacy data, of investigational JAKi-based MF treatment strategies, with a focus on JAKi monotherapies and combinations of novel agents with approved JAKi. Our literature search consisted of extensive review of PubMed and clinicaltrials.gov.Expert opinion: A myriad of promising MF-directed therapies are in late-phase studies. Following their approval, treatment selection should be tailored to patient-specific treatment goals and disease characteristics, with an emphasis on combination therapies of JAKi with novel agents of differing mechanistic targets that possess anti-clonal properties, in attempt to alter disease course and concurrently limit dose-dependent JAKi toxicities.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done? 慢性萎缩性胃炎的现有药物治疗策略透视：还能做得更多吗？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-06-26 DOI: 10.1080/14656566.2024.2373348

Emanuele Dilaghi, Marilia Carabotti, Bruno Annibale

引用次数: 0

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today? 代谢功能障碍相关脂肪性肝病的药物治疗方案：我们的现状如何？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-07-02 DOI: 10.1080/14656566.2024.2374463

Tobias Puengel, Frank Tacke

{"title":"Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?","authors":"Tobias Puengel, Frank Tacke","doi":"10.1080/14656566.2024.2374463","DOIUrl":"10.1080/14656566.2024.2374463","url":null,"abstract":"Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by hepatic steatosis and cardiometabolic risk factors like obesity, type 2 diabetes, and dyslipidemia. Persistent metabolic injury may promote inflammatory processes resulting in metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. Mechanistic insights helped to identify potential drug targets, thereby supporting the development of novel compounds modulating disease drivers.Areas covered: The U.S. Food and Drug Administration has recently approved the thyroid hormone receptor β-selective thyromimetic resmetirom as the first compound to treat MASH and liver fibrosis. This review provides a comprehensive overview of current and potential future pharmacotherapeutic options and their modes of action. Lessons learned from terminated clinical trials are discussed together with the first results of trials investigating novel combinational therapeutic approaches.Expert opinion: Approval of resmetirom as the first anti-MASH agent may revolutionize the therapeutic landscape. However, long-term efficacy and safety data for resmetirom are currently lacking. In addition, heterogeneity of MASLD reflects a major challenge to define effective agents. Several lead compounds demonstrated efficacy in reducing obesity and hepatic steatosis, while anti-inflammatory and antifibrotic effects of monotherapy appear less robust. Better mechanistic understanding, exploration of combination therapies, and patient stratification hold great promise for MASLD therapy.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study. 2 型糖尿病患者的临床和实验室因素与钠-葡萄糖共转运体 2 抑制剂反应之间的关系：一项回顾性观察研究。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-06-05 DOI: 10.1080/14656566.2024.2364054

Sofia Pitsiava, Georgios Dimakopoulos, Vasilis Tsimihodimos, Kalliopi Kotsa, Theocharis Koufakis

{"title":"Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study.","authors":"Sofia Pitsiava, Georgios Dimakopoulos, Vasilis Tsimihodimos, Kalliopi Kotsa, Theocharis Koufakis","doi":"10.1080/14656566.2024.2364054","DOIUrl":"10.1080/14656566.2024.2364054","url":null,"abstract":"Background: This study aimed to investigate the association between clinical and laboratory parameters and response to therapy with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2D).Research design and methods: We retrospectively analyzed the medical records of people with T2D in whom SGLT2i was started. Clinical and laboratory parameters were recorded before, 3 and 6 months after starting treatment. Specific criteria were applied to classify participants into good and poor responders in terms of weight loss (primary outcome) and glycemic control (secondary outcome), separately.Results: Fifty individuals (64% men) with a mean age of 65.8 ± 8.5 years were included in the analysis. 86% and 64% of the participants were classified into good response categories for glycemic control and weight loss, respectively. Good responders in terms of glycemic control had lower high-density lipoprotein cholesterol levels at baseline compared to poor responders (43.3 vs 57.4 mg/dl, p = 0.044). In the logistic regression analysis, a higher baseline weight was associated with a better response to therapy in terms of weight loss (p = 0.04).Conclusions: Our findings suggest that specific clinical and laboratory parameters are associated with response to SGLT2i treatment and can contribute to a more personalized approach to T2D care.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. 银屑病治疗的新型药物疗法和突破：2024 年及以后。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-06-27 DOI: 10.1080/14656566.2024.2373354

Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna

{"title":"Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond.","authors":"Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna","doi":"10.1080/14656566.2024.2373354","DOIUrl":"10.1080/14656566.2024.2373354","url":null,"abstract":"Introduction: The use of the current available therapies for psoriasis management may sometimes be limited by reduced patients' compliance, safety issues for patients' comorbidities, primary lack of efficacy, loss of effectiveness, development of side effects. In this context, several clinical trials investigating the use of both topical and systemic therapies are ongoing, and other new drugs will be approved soon.Areas covered: The aim of this manuscript is to review current literature and to provide an overview of the current and future trends in psoriasis treatment. A comprehensive review of the English-language medical literature was performed using Pubmed and clinicaltrials.gov databases.Expert opinion: Although several therapies are currently available for psoriasis' treatment, unmet needs still exist for patients with moderate and severe psoriasis and hence expanding the therapeutic armamentarium is desirable for a more personalized approach. The ongoing development of innovative therapies could provide effective and safe therapies in the future enhancing the therapeutic management of moderate-severe unresponsive psoriasis.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the pharmacological management of acute respiratory distress syndrome. 急性呼吸窘迫综合征药物治疗的最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-07-01 DOI: 10.1080/14656566.2024.2374461

Denise Battaglini, Ida Giorgia Iavarone, Patricia R M Rocco

{"title":"An update on the pharmacological management of acute respiratory distress syndrome.","authors":"Denise Battaglini, Ida Giorgia Iavarone, Patricia R M Rocco","doi":"10.1080/14656566.2024.2374461","DOIUrl":"10.1080/14656566.2024.2374461","url":null,"abstract":"Introduction: Acute respiratory distress syndrome (ARDS) is characterized by acute inflammatory injury to the lungs, alterations in vascular permeability, loss of aerated tissue, bilateral infiltrates, and refractory hypoxemia. ARDS is considered a heterogeneous syndrome, which complicates the search for effective therapies. The goal of this review is to provide an update on the pharmacological management of ARDS.Areas covered: The difficulties in finding effective pharmacological therapies are mainly due to the challenges in designing clinical trials for this unique, varied population of critically ill patients. Recently, some trials have been retrospectively analyzed by dividing patients into hyper-inflammatory and hypo-inflammatory sub-phenotypes. This approach has led to significant outcome improvements with some pharmacological treatments that previously failed to demonstrate efficacy, which suggests that a more precise selection of ARDS patients for clinical trials could be the key to identifying effective pharmacotherapies. This review is provided after searching the main studies on this topics on the PubMed and clinicaltrials.gov databases.Expert opinion: The future of ARDS therapy lies in precision medicine, innovative approaches to drug delivery, immunomodulation, cell-based therapies, and robust clinical trial designs. These should lead to more effective and personalized treatments for patients with ARDS.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome. 目前和未来治疗以便秘为主的肠易激综合征的药物疗法。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-06-13 DOI: 10.1080/14656566.2024.2366993

Olga Biniszewska, Damian Jacenik, Aleksandra Tarasiuk, Jakub Fichna

{"title":"Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome.","authors":"Olga Biniszewska, Damian Jacenik, Aleksandra Tarasiuk, Jakub Fichna","doi":"10.1080/14656566.2024.2366993","DOIUrl":"10.1080/14656566.2024.2366993","url":null,"abstract":"Introduction: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder affecting 9-23% of the world's population, with a higher prevalence among women. IBS is a complex disorder influenced by psychosocial, physiological, and genetic factors, exacerbated by stress.Areas covered: Research confirms that the most common subtype of IBS is IBS-C. Therefore, new therapies are being developed to speed up bowel movement and reduce constipation, with drugs such as linaclotide, plecanatide, lubiprostone, or tegaserod available to reduce IBS-C symptoms. In addition, patients' condition is improved by foods rich in fiber and low in FODMAP and the use of biotics.Expert opinion: The topic is of great importance due to the growing number of patients suffering from IBS-C and its significant impact on quality of life. Current clinical trials of new therapeutic options are not too successful, and it seems that one of the plausible treatment options could be the multi-drug cocktail with some, or perhaps even all its ingredients emerging from drug re-purposing. Another important path that needs to be explored further in IBS-C patients is the adjustment of dietary habits and/or introduction of dietary or nutritional intervention.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors. 非小细胞肺癌药物疗法的最新进展：关注新出现的微管蛋白抑制剂。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-06-27 DOI: 10.1080/14656566.2024.2369196

Simone Nardin, Gianluca Sacco, Agostina Lagodin D'Amato, Lucrezia Barcellini, Matteo Rovere, Sara Santamaria, Silvia Marconi, Simona Coco, Carlo Genova

{"title":"Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors.","authors":"Simone Nardin, Gianluca Sacco, Agostina Lagodin D'Amato, Lucrezia Barcellini, Matteo Rovere, Sara Santamaria, Silvia Marconi, Simona Coco, Carlo Genova","doi":"10.1080/14656566.2024.2369196","DOIUrl":"10.1080/14656566.2024.2369196","url":null,"abstract":"Introduction: The treatment landscape of non-small cell lung cancer (NSCLC) has seen significant advancements in recent years, marked by a shift toward target agents and immune checkpoint inhibitors (ICIs). However, chemotherapy remains a cornerstone of treatment, alone or in combination. Microtubule-targeting agents, such as taxanes and vinca alkaloids, play a crucial role in clinical practice in both early and advanced settings in NSCLC.Area covered: This review outlines the mechanisms of action, present significance, and prospective advancements of microtubule-targeting agents (MTAs), with a special highlight on new combinations in phase 3 trials. The online databases PubMed, Web of Science, Cochrane Library, and ClinicalTrials.gov were searched using the terms 'Microtubule-targeting agents' and 'non-small cell lung cancer' or synonyms, with a special focus over the last 5 years of publications.Expert opinion: Despite the emergence of immunotherapy, MTA remains crucial, often used alongside or after immunotherapy, especially in squamous cell lung cancer. Next-generation sequencing expands treatment options, but reliable biomarkers for immunotherapy are lacking. While antibody-drug conjugates (ADCs) show promise, managing toxicities remain vital. In the early stages, MTAs, possibly with ICIs, are standard, while ADCs may replace traditional chemotherapy in the advanced stages. Nevertheless, MTAs remain essential in subsequent lines or for patients with contraindications.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies. 骨关节炎相关疼痛的药物疗法：现有疗法和新兴疗法。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-07-10 DOI: 10.1080/14656566.2024.2374464

Mengdi Zhang, Zhiqiang Wang, Changhai Ding

{"title":"Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies.","authors":"Mengdi Zhang, Zhiqiang Wang, Changhai Ding","doi":"10.1080/14656566.2024.2374464","DOIUrl":"10.1080/14656566.2024.2374464","url":null,"abstract":"Introduction: Osteoarthritis (OA) related pain has affected millions of people worldwide. However, the current pharmacological options for managing OA-related pain have not achieved a satisfactory effect.Areas covered: This narrative review provides an overview of the current and emerging drugs for OA-related pain. It covers the drugs' mechanism of action, safety, efficacy, and limitations. The National Library of Medicine (PubMed) database was primarily searched from 2000 to 2024.Expert opinion: Current treatment options are limited and suboptimal for OA pain management. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are the recognized and first-line treatment in the management of OA-related pain, and other drugs are inconsistent recommendations by guidelines. Emerging treatment options are promising for OA-related pain, including nerve growth factor (NGF) inhibitors, ion channel inhibitors, and calcitonin gene-related peptide (CGRP) antagonists. Besides, drugs repurposing from antidepressants and antiepileptic analgesics are shedding light on the management of OA-related pain. The management of OA-related pain is challenging as pain is heterogeneous and subjective. A more comprehensive strategy combined with non-pharmacological therapy needs to be considered, and tailored management options to individualized patients.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0